Intra-Cellular Therapies Inc. ($ITCI) Stock Forecast: Up 6.5% Today

What is Intra-Cellular Therapies Inc.?

Intra-Cellular Therapies (ITCI) is a biopharmaceutical company specializing in therapeutics for central nervous system disorders. Today, the stock experienced a strong bullish movement.

Why is Intra-Cellular Therapies Inc. going up?

ITCI stock is up 6.5% on Jan 10, 2025 14:55

• Settlement of CAPLYTA® patent litigation with Sandoz likely provided a positive resolution and removed uncertainty for Intra-Cellular Therapies, boosting investor confidence.
• Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference may have showcased the company's innovative pipeline and future growth prospects, attracting investors' interest.
• These positive developments could have led to increased optimism surrounding Intra-Cellular Therapies' potential for revenue generation and market expansion, driving the bullish movement in the stock price.

ITCI Price Chart

ITCI Technical Analysis

ITCI News

Intra-Cellular Therapies Settles CAPLYTA® ( lumateperone ) Patent Litigation with Sandoz

BEDMINSTER, N.J., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Intra-Cellular Therapies, Inc. ( Nasdaq: ITCI ) , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders, today announced that it has entered into a settlement ...

https://www.globenewswire.com/news-release/2025/01/10/3007508/30597/en/Intra-Cellular-Therapies-Settles-CAPLYTA-lumateperone-Patent-Litigation-with-Sandoz.html

Intra-Cellular Therapies Settles CAPLYTA® ( lumateperone ) Patent Litigation with Sandoz - Intra-Cellular Therapies ( NASDAQ:ITCI )

BEDMINSTER, N.J., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Intra-Cellular Therapies, Inc.

https://www.benzinga.com/pressreleases/25/01/g42908296/intra-cellular-therapies-settles-caplyta-lumateperone-patent-litigation-with-sandoz

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Intra-Cellular Therapies ( NASDAQ:ITCI )

BEDMINSTER, N.J., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Intra-Cellular Therapies, Inc. ITCI, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer ...

https://www.benzinga.com/pressreleases/25/01/g42811656/intra-cellular-therapies-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDMINSTER, N.J., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Intra-Cellular Therapies, Inc. ( Nasdaq: ITCI ) , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders, today announced that Sharon Mates, Ph.D., Chief ...

https://www.globenewswire.com/news-release/2025/01/06/3004596/30597/en/Intra-Cellular-Therapies-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

Trending Today

Steel Dynamics Inc. ($STLD) Stock Forecast: Up 5.5% Today

Solana ($SOL) Crypto Forecast: Down 5.9% Today

Halliburton Company ($HAL) Stock Forecast: Up 2.9% Today

DexCom Inc. ($DXCM) Stock Forecast: Down 5.8% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Down 5.7% Today

Valero Energy Corporation ($VLO) Stock Forecast: Up 4.9% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Up 4.8% Today

Uniswap ($UNI) Crypto Forecast: Down 8.5% Today

Northrop Grumman Corporation ($NOC) Stock Forecast: Up 3.1% Today

Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Down 1.9% Today

Intra-Cellular Therapies Inc. Price History

25.05.2024 - ITCI Stock was down 5.2%

• An insider selling over $1.5 million in company shares could have prompted investor worries about the company's future and influenced the negative market sentiment.
• Although the RS rating was raised to 87, signaling strong technical performance, the director's selling activity may have outweighed this positive news.
• Following a 9.6% increase in stock price in the previous trading session, some investors may have chosen to take profits today, contributing to the decline.
• The bearish movement in ITCI stock today could be attributed to a combination of profit-taking, the director's stock sale, and potential investor apprehensions about the company's future performance.

10.06.2024 - ITCI Stock was up 5.5%

• Analysts project a 30.14% upside potential for ITCI.
• Positive trend in earnings estimate revisions is enhancing the optimistic outlook on the stock.
• Growing confidence in the company's pipeline of treatments for neuropsychiatric disorders may be driving the bullish movement.

06.08.2024 - ITCI Stock was up 2.4%

• The upward trend in ITCI's performance may be linked to favorable updates regarding its CNS disorder treatments pipeline.
• Analyst outlook alterations and upgrades in related firms might have enhanced investor trust in the pharmaceutical industry, resulting in heightened attention towards ITCI.
• The optimistic market sentiment towards healthcare stocks, demonstrated by analyst upgrades, likely influenced the positive momentum observed in ITCI.

10.00.2025 - ITCI Stock was up 6.5%

• Settlement of CAPLYTA® patent litigation with Sandoz likely provided a positive resolution and removed uncertainty for Intra-Cellular Therapies, boosting investor confidence.
• Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference may have showcased the company's innovative pipeline and future growth prospects, attracting investors' interest.
• These positive developments could have led to increased optimism surrounding Intra-Cellular Therapies' potential for revenue generation and market expansion, driving the bullish movement in the stock price.

09.04.2024 - ITCI Stock was down 5.1%

• ITCI exceeded earnings and revenue estimates for Q1 2024 but still faced a bearish trend.
• Despite reporting strong Caplyta sales, Intra-Cellular Therapies struggled to counter the negative market sentiment.
• Jefferies' $105 target price and buy rating for ITCI did not influence the stock positively.
• The market reacted negatively to Intra-Cellular Therapies Inc.'s $15.2 million loss, emphasizing a shift towards profitability rather than solely focusing on revenue growth.

08.04.2024 - ITCI Stock was down 5.3%

• Despite outperforming earnings per share (EPS) and revenue projections in Q1 2024, Intra-Cellular Therapies (ITCI) witnessed a significant decline in its stock price.
• The maintenance of a $105 target price and buy rating by Jefferies did not have a notable impact on the stock's performance.
• Strong sales of CAPLYTA, a key product of Intra-Cellular, resulted in revenue surpassing expectations but did not lead to a bullish market response.
• The Q1 reported loss of $15.2 million may have overshadowed the positive revenue results, contributing to the bearish sentiment surrounding ITCI stock.

18.03.2024 - ITCI Stock was down 8.4%

• A public offering of common stock by Intra-Cellular Therapies could have increased selling pressure, influencing the bearish movement.
• Despite a target increase for Intra-Cellular shares by Baird, profit-taking activities following a stock price surge might have affected market sentiment.
• The positive news regarding the depression drug meeting study goals might already have been factored into the stock price, potentially leading to a "buy the rumor, sell the news" trend.
• Amidst higher U.S. stock futures signaling general market optimism, investor attention may have shifted away from individual biopharmaceutical stocks such as Intra-Cellular Therapies, contributing to the bearish movement.

18.05.2024 - ITCI Stock was up 12.6%

• Intra-Cellular Therapies released positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy for major depressive disorder (MDD), leading to increased investor optimism.
• The successful Phase 3 trial results for lumateperone in treating depression created a $1.7 billion opportunity, driving the stock price higher.
• The company's announcement of statistically significant and clinically meaningful results in the Phase 3 trial further boosted investor confidence in the potential of lumateperone as a treatment for MDD.
• The anticipation of submitting a supplemental FDA application in the near future added to the positive sentiment surrounding Intra-Cellular Therapies, contributing to the bullish movement in ITCI stock.

18.05.2024 - ITCI Stock was up 9.6%

• Intra-Cellular Therapies Inc's stock rallied by 15% following the successful results of its depression drug in the second late-stage study. This positive outcome positions the company to tap into a significant market opportunity, potentially leading to substantial sales growth.
• The company's announcement of successful data from the second depression study, along with the anticipation of submitting a supplemental FDA application, generated investor optimism and drove the stock price higher.
• The market reacted positively to the news of Intra-Cellular Therapies' Phase 3 win in depression treatment, highlighting the potential of its FDA-approved mood disorder therapy. This success in the trial further fueled investor confidence in the company's future prospects, contributing to the bullish movement in the stock price.

18.05.2024 - ITCI Stock was up 6.0%

• ITCI stock surged today following the announcement of positive topline results in the second Phase 3 trial evaluating Lumateperone as adjunctive therapy in patients with Major Depressive Disorder (MDD).
• The statistically significant and clinically meaningful results in Study 502, with Lumateperone 42 mg meeting primary and key secondary endpoints, have boosted investor confidence in the drug's efficacy.
• The anticipation of a submission for a New Drug Application (NDA) in late 2024 has further fueled optimism around the potential commercial success of Lumateperone, driving the bullish momentum in ITCI stock.

25.06.2024 - ITCI Stock was up 5.1%

• ITCI stock saw an increase in value today.
• The announcement of hosting the second-quarter 2024 financial results conference call and webcast likely boosted investor confidence.
• Positive investor sentiment may stem from expected updates on the progress in CNS disorder treatment and financial performance, driving higher buying interest.
• The bullish trend in ITCI stock could be linked to the market's excitement surrounding potential insights from the upcoming conference call.

07.07.2024 - ITCI Stock was down 5.2%

• The appointment of Sanjeev Narula as the new Chief Financial Officer may have raised concerns among investors about potential changes in financial strategies or uncertainties about the company's future financial performance.
• The reported loss of $16.2 million in Q2 earnings could have contributed to the bearish sentiment, indicating possible financial challenges or lower-than-expected revenue generation.
• The market might be reacting to the retirement of the current CFO and the need for a smooth transition, leading to uncertainty about the financial stability and leadership continuity within Intra-Cellular Therapies.
• Investors may be cautious about the impact of these recent developments on the company's growth prospects and overall financial health, leading to a bearish trend in the stock price.